<DOC>
	<DOCNO>NCT02609152</DOCNO>
	<brief_summary>The main objective study evaluate effectiveness administration short act beta-blocker term effective increase stroke volume ( least 15 % ) 4 hour initiation therapy septic shock patient hyperkinetic profile 12-24 hour care . This research seek demonstrate proportion patient increase systolic ejection superior equal 15 % ( relative baseline ) four hour different two arm study : ( 1 ) experimental arm patient receive esmolol infusion accord predetermined procedure ( 2 ) control arm patient receive saline infusion accord predetermined procedure .</brief_summary>
	<brief_title>Effect Continuous Infusion Esmolol Stroke Volume Patients With Hyperdynamic Vasoplegic Septic Shock</brief_title>
	<detailed_description>The secondary objective compare follow item two arm study : A . Central venous oxygen saturation 4 hour ( H4 ) B . Changes plasma concentration lactate H0 H4 C. Changes tissue oxygen saturation H0 H4 D. Changes echocardiographic parameter systolic function leave ventricle ( LV ) right ventricle ( RV ) , well diastolic LV function H0 H4 E. Vascular Filling volume study period F. Kidney function : urine output creatinine change H0 H4 G. The required vasopressor time H0 H4 H. Use positive inotropic agent I . The inflammatory response via analysis HLA-DR H0 H4 M1 / M2 responses H4 J . The duration ICU stay , mortality , morbidity term organ failure</detailed_description>
	<mesh_term>Shock</mesh_term>
	<mesh_term>Shock , Septic</mesh_term>
	<mesh_term>Esmolol</mesh_term>
	<criteria>The patient his/her representative inform implementation study , objective , constraint patient right emergency consent The patient his/her representative must give free informed consent sign consent emergency consent The patient must affiliate recipient health insurance plan Septic shock criterion : shock suspect proven start point infection require vasopressor adequate fluid resuscitation start within past 24 72 hour Precharge independence criterion obtain : i.e . pulsed pressure variation &lt; 13 % variation ejection volume &lt; 10 % variation cardiac index passive lift leg &lt; 10 % central venous pressure 8 12 mmHg . Antibiotic treatment progress Prescription ongoing vasopressor 24 72 hour . Sinus rhythm Heart rate &gt; 100 beat per minute Cardiac Index measure thermodilution great 4.0 l / min / m^2 Central venous oxygen saturation &gt; 80 % without positive inotropics dobutamine isoproterenol ( continuously take measure via central venous line superior vena cava territory ) two successive sample 12 hour Monitoring stroke volume ( invasive , semiinvasive ultrasound ) The patient participate another study The patient participate another study last 3 month The patient exclusion period determine previous study The patient kind guardianship The patient judicial protection The patient his/her representative refuse sign consent It impossible correctly inform patient The patient pregnant , parturient , breastfeed The patient contraindication treatment use study Cardiac index &lt; 4.0 l / min / m^2 Need introduce positive inotropic agent ( determined physician charge patient ) Contraindications use esmolol : Severe sinus bradycardia ( le 50 beat per minute ) ; Sinus pathology , severe disorder atrioventricular conduction ( without pacemaker ) , atrioventricular block second third degree ; Cardiogenic shock ; Severe hypotension ; Decompensated heart failure ; Untreated pheochromocytoma ; Pulmonary hypertension ; Acute asthma attack ; chronic obstructive pulmonary disease ; peripheral arterial disease ; Metabolic acidosis ; Known hypersensitivity esmolol . Patient kidney failure ( RIFLE Stage L ) Chronic treatment beta blocker Patient ultrasound assessment leave ventricular ejection fraction &lt; 40 %</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>